Company: BIVIW
Filing Date: 2025-07-22
Form Type: S-1/A
Source: 0001520138-25-000216
Chunk: 56

Company: BIOVIE INC.
Filing Date: 2025-07-22
Form: S-1/A
Chunk 56
---
 such action to a successful conclusion.
Uncertainties resulting from the initiation and continuation of any litigation could limit our ability to continue our operations and
you could lose all of your investment.

Some of our competitors are larger than we are
and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent litigation or
proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property
portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing, misappropriating or otherwise
violating our intellectual property. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property
claims could result in substantial costs and diversion of management resources, which could harm our business. In addition, the uncertainties
associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our internal
research programs, or in-license needed technology or other drug candidates. There could also be public announcements of the results of
the hearing, motions, or other interim proceedings or developments. If securities analysts or investors perceive those results to be negative,
it could cause the price of shares of our Common Stock to decline. Any of the foregoing events could harm our business, financial condition,
results of operation and prospects.

<div align='center'>25</div>

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our drug candidates.

We cannot guarantee that any of our or our licensors’
patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant
patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending patent
application in the United States and abroad that is relevant to or necessary for the commercialization of our drug candidates in any jurisdiction.
For example, U.S. patent applications filed before November 29, 2000 and certain U.S. patent applications filed after that date that will
not be filed outside the United States remain confidential until patents issue. As mentioned above, patent applications in the United
States and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest
filing date being commonly referred to as the priority date. Therefore, patent applications covering our drug candidates could have